Hologic Stock News

The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

June has been a strong month for this stock.

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Zacks Medical - Instruments industry is growing on rising demand for digital health. HOLX, MASI and ITGR are set to gain the most.

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Corporate profits in the S&P 500 are coming in strong. So strong, in fact, that some keep blowing away even the analysts' expectations.

Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Investors interested in Medical - Instruments stocks are likely familiar with Hologic (HOLX) and SONOVA HOLDING (SONVY). But which of these two stocks presents investors with the better value opportun

The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.

Hologic, Inc. (NASDAQ:HOLX ) Q2 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Ryan Simon - VP, IR Stephen MacMillan - Chairman, President and CEO Karleen Oberton - CFO Conf

Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street

Hologic (HOLX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $2.07 per share a year ago.